ZURA Zura Bio Ltd
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1855644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-43.7%
TTM EPS YoY-70.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-65.4%
ROA-55.2%
ROIC (approx.)-164.3%
Asset turnover—
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio11.29x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-42.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $42.08M | $24.40M | $44.00M | $23.69M |
| SG&A expense | $33.16M | $30.79M | $18.64M | $3.47M |
| Operating income | -$75.25M | -$55.19M | -$62.64M | -$2.68M |
| Pretax income | -$68.65M | -$52.40M | -$60.56M | -$27.33M |
| Income tax | — | $0 | $0 | — |
| Net income | -$68.65M | -$52.40M | -$60.36M | -$25.70M |
| EBITDA | -$75.20M | -$55.18M | — | — |
| EPS (basic) | -1.06 | -0.60 | -2.09 | -141.97 |
| EPS (diluted) | -1.06 | -0.60 | -2.09 | -141.97 |
| Weighted avg. shares (diluted) | 94.16M | 75.07M | 33.06M | 228,148 |
| Balance sheet | ||||
| Cash & equivalents | $109.41M | $176,498 | $99.81M | $1.57M |
| Current assets | $112.31M | $178.74M | $100.84M | $1.78M |
| PP&E, net | $126,000 | $91,000 | — | — |
| Total assets | $113.95M | $179.53M | $100.84M | $5.26M |
| Current liabilities | $12.41M | $19.51M | $20.30M | $14.82M |
| Total liabilities | $12.41M | $19.51M | $21.29M | $14.82M |
| Shareholders' equity | $101.54M | $146.81M | $59.33M | -$32.06M |
| Shares outstanding | 73.68M | 65.30M | 43.59M | 279,720 |
| Cash flow statement | ||||
| Operating cash flow | -$64.81M | -$28.08M | -$15.05M | -$1.07M |
| Capital expenditure | $113,000 | $75,000 | — | — |
| Free cash flow | -$64.93M | -$28.15M | — | — |
| Investing cash flow | -$113,000 | -$5.08M | -$8.00M | -$12.00M |
| Financing cash flow | -$2.16M | $109.84M | $121.29M | $14.77M |
| Depreciation & amortization | $49,000 | $9,000 | — | — |
| Stock-based compensation | $12.33M | $16.80M | $7.47M | $334,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.